Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,865 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Leukemia
Interventions: bcr-abl peptide vaccine, reverse transcriptase-polymerase chain reaction; Biological · Genetic
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Pain, Lumbar Pain Syndrome, Low Back Pain
Interventions: BioWave, TENS; Device
Lead sponsor: BioWave Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: New Haven, Connecticut • Huntersville, North Carolina • Lancaster, Pennsylvania + 1 more

Conditions: Neuropathic Pain, Spinal Cord Injury
Interventions: Modified-release morphine, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Rib Fractures
Interventions: ESP block with catheter using ropivacaine (bolus followed by continuous infusion), Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h; Procedure · Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 55 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hereditary Hemorrhagic Telangiectasia
Interventions: Bevacizumab (Avastin®); Drug
Lead sponsor: Hanny Al-Samkari, MD; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions: Life completion and preparation, Attention Control; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: Gemcitabine, Sorafenib, Placebo, Capecitabine; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 44
States / cities: Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more

Conditions: Colorectal Cancer
Interventions: Patient Navigation; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 52 Years to 79 Years
Enrollment: 1,223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chelsea, Massachusetts

Conditions: Hypertriglyceridemia
Interventions: Omega-3-acid ethyl esters, Placebo; Drug
Lead sponsor: Babu Balagopal; Other
Eligibility: 10 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: Wilmington, Delaware • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Adolescent Behavior, Mental Health Issue
Interventions: Navigation Arm, Control Arm; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 4 Years to 12 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Oakland, California • Seattle, Washington

Conditions: Elbow Tendinopathy
Interventions: Floss band, ACE bandage; Device
Lead sponsor: New York Institute of Technology; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Old Westbury, New York

Conditions: HIV
Interventions: Treatment Advocacy; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions: Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 28 Days and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Cognitive Impairment
Interventions: Speed of Processing Training, Transfer Package from CI Therapy; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metastatic Breast Cancer
Interventions: Pegylated liposomal doxorubicin, Capecitabine; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 60 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 27
States / cities: Fountain Valley, California • Oxnard, California • Soquel, California + 24 more

Conditions: CKD Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Tempe, Arizona • Alhambra, California + 48 more

Conditions: Acromegaly
Interventions: ALXN2420, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Torrance, California • Ann Arbor, Michigan

Conditions: Breast Cancer, Brain Metastases, HER2-positive Breast Cancer, CNS Disease
Interventions: Tucatinib, Pembrolizumab, Trastuzumab; Drug
Lead sponsor: Reva Basho; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Diseases, Interstitial
Interventions: Nintedanib, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more

Conditions: Liver Cirrhosis
Interventions: Zibotentan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Adenocarcinoma of Lung, Lung Cancer
Interventions: Oral Restorative Microbiota Therapy (RMT) Capsules, Durvalumab 1500 mg IV, Cisplatin/pemetrexed or Carboplatin/pemetrexed, Placebo; Drug · Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Irritable Bowel Syndrome, Dyspepsia, Functional Bloating
Interventions: Biofeedback, Placebo; Behavioral
Lead sponsor: Hospital Universitari Vall d'Hebron Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: ASCVD, Diabetes
Interventions: SMS (Initial Outreach), Secure Portal Message (Initial Outreach), Non-secure Email (Initial Outreach), SMS (Follow-up for Non-responders), Secure Portal Message (Follow-up for Non-responders), Non-secure Email (Follow-up for Non-responders); Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 22,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pleasant Hill, California

Search by objective public record fields.

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

BioWave High-frequency Neurostimulation Versus TENS for the Treatment of Chronic Low Back Pain

Effectiveness of Controlled-Release Morphine for Chronic Neuropathic Pain After Spinal Cord Injury

Analgesic Techniques for Rib Fractures

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Outlook Quality of Life Intervention

1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

Colorectal Cancer Screening Navigator Program for Low Income and Non-English Speaking Populations

Fish Oil Study for High Triglyceride Levels in Children

Assisted Identification and Navigation of Early Mental Health Symptoms in Children

Effect of Tissue Flossing on Pain,Function and Movement

Treatment Advocacy Intervention for HIV-Positive African Americans

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Improving Thinking in Everyday Life: Pilot Study A

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

Visible Abdominal Distension

Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease